Baidu
map

Neurology:儿童和成人发病的多发性硬化症患者生活质量的决定因素

2019-11-17 xing.T MedSci原创

由此可见,POMS患者和AOMS患者的QoL无差异。该研究结果支持通过减少神经系统残疾和改善心理状况来改善MS患者QoL的方法。

近日,神经病学领域权威取杂志Neurology上发表了一篇研究文章,研究人员旨在通过EQ-5D来评估成年儿童发病多发性硬化症(POMS)或成年发病多发性硬化症(AOMS)患者的生活质量(QoL),并探讨两组患者QoL的决定因素。

数据来自瑞典全国多发性硬化症(MS)登记中心,研究人员收集了人口统计学特征、EQ-5D-3水平、多发性硬化症影响量表(MSIS-29)评分、扩展残疾状况量表(EDSS)评分、符号数字模式测试评分、复发和疾病缓解疗法(DMT)暴露量,大约每年收集一次(2011-2019年)。研究人员纳入了年龄介于18至50岁之间且EQ-5D≥2明确诊断的MS患者。该研究的主要结局是EQ-5D视觉模拟量表(EQ-VAS)得分。线性混合模型比较了POMS患者和AOMS患者之间所有可用的EQ-VAS得分,以及POMS患者和AOMS患者之间EQ-VAS决定因素(单独评估)。

该研究总共有5094人符合纳入标准:354人(6.9 %)为POMS。该研究共记录了21357个独特的EQ-5D分数。大多数参与者为女性(70.0%),具有复发性疾病病程(98.1%)。校正混杂因素后,POMS患者和AOMS患者之间的EQ-VAS评分无差异(POMS患者与AOMS患者的β系数[参考]为0.99;95%置信区间为0.89至2.87)。经历复发、严重的神经系统残疾(EDSS≥6.0 vs. <3.0)以及较高的MSIS-29心理评分与较低的QoL相关,而较高的信息处理效率和接受一线DMT治疗与较高的QoL评分相关。

由此可见,POMS患者和AOMS患者的QoL无差异。该研究结果支持通过减少神经系统残疾和改善心理状况来改善MS患者QoL的方法。 

原始出处:

Kyla A. McKay,et al.Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.Neurology.2019.https://doi.org/10.1212/WNL.0000000000008537

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983085, encodeId=e51b198308584, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Oct 03 21:27:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890074, encodeId=361a18900e4e9, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Jun 30 17:27:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671038, encodeId=647916e103811, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Mon Nov 02 06:27:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000917, encodeId=2054200091efd, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Apr 16 17:27:00 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983085, encodeId=e51b198308584, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Oct 03 21:27:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890074, encodeId=361a18900e4e9, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Jun 30 17:27:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671038, encodeId=647916e103811, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Mon Nov 02 06:27:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000917, encodeId=2054200091efd, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Apr 16 17:27:00 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2020-06-30 jml2009
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983085, encodeId=e51b198308584, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Oct 03 21:27:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890074, encodeId=361a18900e4e9, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Jun 30 17:27:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671038, encodeId=647916e103811, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Mon Nov 02 06:27:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000917, encodeId=2054200091efd, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Apr 16 17:27:00 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983085, encodeId=e51b198308584, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Oct 03 21:27:00 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890074, encodeId=361a18900e4e9, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Tue Jun 30 17:27:00 CST 2020, time=2020-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671038, encodeId=647916e103811, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Mon Nov 02 06:27:00 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000917, encodeId=2054200091efd, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Apr 16 17:27:00 CST 2020, time=2020-04-16, status=1, ipAttribution=)]
    2020-04-16 yinhl1978

相关资讯

Lancet haemat:3期试验:利伐沙班治疗静脉血栓栓塞儿童的临床预后和安全性

儿童静脉血栓栓塞的治疗是基于从成人中获得的数据,几乎没有直接的文献证明其在儿童中的有效性和安全性。现研究人员对利伐沙班 vs 标准抗凝剂治疗静脉血栓栓塞儿童的疗效和安全性。本研究是一项多中心的、平行组、非盲的随机化研究,从28个国家的107家儿科医院招募已开始肝素治疗的急性静脉血栓栓塞的儿童(0-17岁),按2:1随机分至利伐沙班组或标准抗凝剂组。持续治疗3个月(2岁以下患儿1个月)。主要疗效预后

Clin Respir J:哮喘和过敏性鼻炎儿童中与呼出一氧化氮相关的因素研究

导致呼出一氧化氮(FeNO)水平变化的相关因素在不同年龄段的哮喘儿童中仍具缺乏报道。最近,有研究人员在具有过敏性鼻炎的哮喘儿童中评估了与FeNO相关的因素和FeNO对吸入性类固醇的响应情况。研究包括了5岁到12岁的哮喘儿童。研究人员测试了FeNO、肺功能和对乙酰甲胆硷的支气管高反应性(BHR)、气源性过敏原的皮刺测试、血清中总免疫球蛋白E(T-lgE)和血液中的嗜酸性粒细胞水平,并评估了FeNO与

Eur Ann Allergy Clin Immunol:过敏性鼻炎在渗出性中耳炎儿童中的患病率分析

过敏性鼻炎在渗出性中耳炎儿童中的患病率在不同的国家中范围为82%到93%。之前的研究已经鉴定和证明了许多渗出性中耳炎的风险因子。然而,与过敏性鼻炎的相关性仍旧存在争议。最近,有研究人员确定了渗出性中耳炎儿童中过敏性鼻炎的患病率情况,并鉴定了渗出性中耳炎的相关风险因子,与过敏性鼻炎相关的常见过敏原,还确定了渗出性中耳炎儿童的听力阈值。研究共包括了130名儿童。研究发现,渗出性中耳炎儿童中过敏性鼻炎的

Int J Pediatr Otorhinolaryngol:特殊和主流教育中听力损失儿童生活质量研究

最近,有研究人员比较了正常听力(NH)儿童和听力损失儿童(HL)生活质量(QoL)的情况,并调查了具有HL的儿童的QoL随着时间是怎样变化的,其中考虑到了语言技巧,听力设备类型,HL程度和教育类型。研究是一个纵向的研究。研究发现,HL儿童和NH儿童的QoL在4个QoL模块中的2个中相似,即情绪和身体功能2个模块。在另外2个模块,社交和学校功能中,特殊教育的HL的儿童和转变为主流教育的儿童得分比那些

JAMA Ophthalmol:二手烟危害儿童眼睛

二手烟的危害可谓罄竹难书,近日一项来自香港中文大学的研究又添一条罪证:二手烟危害儿童眼睛。

Diabetes Care:儿童胰腺炎与成年后糖尿病风险

由此可见,青春期晚期胰腺功能正常但儿童期存在急性胰腺炎病史是发生2型糖尿病的危险因素,尤其是在年轻成人中。

Baidu
map
Baidu
map
Baidu
map